Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Completed · Phase 2

Conditions studied: Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Drugs used in chemotherapy, such as amifostine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well amifostine works in treating young patients with newly diagnosed de novo myelodysplastic syndromes.

Key facts

Study ID
NCT00098683
Run by
Children's Oncology Group
People needed
10
Starts
2005-01-01
Expected to finish
2009-10-01
Last updated by the study team
2014-02-13

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.